Skip to content
Commercial Litigation Woods Lonergan LLP

212.684.2500

Copyright Litigation

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in ... - GlobeNewswire (press release)

January 3, 2018 - 1:16am

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in ...
GlobeNewswire (press release)
In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory ...

and more »

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in ... - GlobeNewswire (press release)

January 3, 2018 - 1:16am

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in ...
GlobeNewswire (press release)
In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory ...

and more »

Trevena Announces FDA Acceptance for Review of New Drug Application for OLINVO™ (oliceridine) Injection - GlobeNewswire (press release)

January 2, 2018 - 4:01pm

Trevena Announces FDA Acceptance for Review of New Drug Application for OLINVO™ (oliceridine) Injection
GlobeNewswire (press release)
... expectations for regulatory approvals, including with respect to the OLINVO NDA and the timing of the PDUFA date; availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure ...

and more »

Lexicon Pharmaceuticals Announces Poster Presentation at ASCO GI - GlobeNewswire (press release)

January 2, 2018 - 4:01pm

Lexicon Pharmaceuticals Announces Poster Presentation at ASCO GI
GlobeNewswire (press release)
Other risks include Lexicon's ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other potential drug candidates, achieve its operational objectives ...

and more »

Elite Pharmaceuticals Announces FDA Approval of Phendimetrazine Tartrate Tablets USP - GlobeNewswire (press release)

January 2, 2018 - 12:56pm

Elite Pharmaceuticals Announces FDA Approval of Phendimetrazine Tartrate Tablets USP
GlobeNewswire (press release)
These risks and other factors, including, without limitation, Elite's ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by ...

and more »

ASMI Share Buyback Update December 25-29, 2017 - GlobeNewswire (press release)

January 2, 2018 - 11:45am

ASMI Share Buyback Update December 25-29, 2017
GlobeNewswire (press release)
These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the ...

and more »

AIT Therapeutics Appoints Yoori Lee to its Board of Directors - GlobeNewswire (press release)

January 2, 2018 - 9:45am

AIT Therapeutics Appoints Yoori Lee to its Board of Directors
GlobeNewswire (press release)
Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to: our approach to discover and develop novel drugs, which is unproven ...

and more »

Predictive Technology Group Appoints Dr. Michael Dey To Board Of ... - GlobeNewswire (press release)

January 2, 2018 - 9:02am

GlobeNewswire (press release)

Predictive Technology Group Appoints Dr. Michael Dey To Board Of ...
GlobeNewswire (press release)
Predictive Technology Group, Inc. (OTC PINK: PRED), announces the appointment of Michael Dey, Ph.D. to the Board of Directors of Predictive Technology Group, Inc. Dr. Dey will assist in corporate governance and guide the development and ...

and more »

Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency - GlobeNewswire (press release)

January 2, 2018 - 8:30am

Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
GlobeNewswire (press release)
... achievement of the results it anticipates from its preclinical development and clinical trials of its product candidates, the receipt of regulatory approvals, its ability to adequately obtain and protect its intellectual property rights, and other ...

and more »

Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study ... - GlobeNewswire (press release)

January 2, 2018 - 8:30am

Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study ...
GlobeNewswire (press release)
NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, today announced that it has completed ...

and more »

Selecta Biosciences Announces FDA Acceptance of Investigational ... - GlobeNewswire (press release)

January 2, 2018 - 8:05am

Selecta Biosciences Announces FDA Acceptance of Investigational ...
GlobeNewswire (press release)
WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced ...

and more »

Selecta Biosciences Announces CEO's Intent to Retire and Transition Plan - GlobeNewswire (press release)

January 2, 2018 - 8:01am

Selecta Biosciences Announces CEO's Intent to Retire and Transition Plan
GlobeNewswire (press release)
... its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the company's inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its ...

and more »

Melinta Therapeutics Appoints Lisa DeFrancesco as Senior Vice President of Investor Relations - GlobeNewswire (press release)

January 2, 2018 - 7:00am

Melinta Therapeutics Appoints Lisa DeFrancesco as Senior Vice President of Investor Relations
GlobeNewswire (press release)
... Company's products may not be as large as expected; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain ...

and more »

Lexicon Pharmaceuticals to Present at Upcoming Investor ... - GlobeNewswire (press release)

January 2, 2018 - 7:00am

Lexicon Pharmaceuticals to Present at Upcoming Investor ...
GlobeNewswire (press release)
THE WOODLANDS, Texas, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference: 36th Annual J.P. Morgan Healthcare ...

and more »

Veru Reports Fiscal 2017 Fourth-Quarter, Full-Year Financial ... - GlobeNewswire (press release)

January 2, 2018 - 7:00am

Veru Reports Fiscal 2017 Fourth-Quarter, Full-Year Financial ...
GlobeNewswire (press release)
MIAMI, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU) today announced its financial results for the fiscal 2017 fourth quarter and full year ended September 30, 2017. “Our fiscal 2017 financial results reflect the risk and volatility ...

and more »

BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular Carcinoma - GlobeNewswire (press release)

January 2, 2018 - 6:00am

BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular Carcinoma
GlobeNewswire (press release)
... which may not support further development; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; BeiGene's ability to achieve market acceptance in the medical community necessary for commercial ...

and more »

Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA® (iobenguane I 131) in ... - GlobeNewswire (press release)

December 29, 2017 - 8:30am

KL Daily

Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA® (iobenguane I 131) in ...
GlobeNewswire (press release)
... market acceptance for approved products; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby; generic and other competition; the possible impairment of ...
Zacks' Top 10 Stocks for 2018Zacks.com
Progenics Pharmaceuticals Inc. - PGNX - Stock Price Today - ZacksZacks Investment Research
PGNX Progenics Pharmaceuticals, Inc. Stock Quote - FinvizFinviz

all 69 news articles »

After Trump criticism, China denies selling oil illicitly to North Korea - Reuters

December 29, 2017 - 7:39am

Reuters

After Trump criticism, China denies selling oil illicitly to North Korea
Reuters
That doesn't include the theft of intellectual property, O.K., which is another $300 billion,” Trump said, according to a transcript of the interview. “If they're helping me with North Korea, I can look at trade a little bit differently, at least for a ...

and more »

After Trump criticism, China says no illicit oil sales to North Korea - CBC.ca

December 29, 2017 - 7:24am

CBC.ca

After Trump criticism, China says no illicit oil sales to North Korea
CBC.ca
In the Times interview, Trump explicitly tied his administration's trade policy with China to its perceived co-operation in resolving the North Korea nuclear crisis. "When I campaigned, I was very tough on China in terms of trade. They made — last ...
Donald J. Trump on Twitter: "Caught RED HANDED - very disappointed that China is allowing oil to go into North Korea ...Twitter
Chinese Ships Spotted Selling Oil to N.KoreaThe Chosun Ilbo

all 958 news articles »

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the ... - GlobeNewswire (press release)

December 29, 2017 - 7:00am

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the ...
GlobeNewswire (press release)
This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or ...

and more »